Logo-apb
Adv Pharm Bull. 2020;10(1): 20-29.
doi: 10.15171/apb.2020.003
PMID: 32002358
PMCID: PMC6983984
Scopus ID: 85084127368
  Abstract View: 721
  PDF Download: 581

Research Article

Formulation and Evaluation of Eudragit RL-100 Nanoparticles Loaded In-Situ Forming Gel for Intranasal Delivery of Rivastigmine

Sara Salatin 1,2 ORCID logo, Jaleh Barar 1,3*, Mohammad Barzegar-Jalali 3, Khosro Adibkia 3,4, Mitra Alami-Milani 3, Mitra Jelvehgari 3,4* ORCID logo

1 Research Center for Pharmaceutical Nanotechnology Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Department of Pharmaceutics, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
4 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
*Corresponding Authors: Jaleh Barar and Mitra Jelvehgari, Tel: +98 41 33392585. Fax: +98 41 33344798, E-mail: jbarar@tbzmed.ac.ir, E-mail: jbarar@tbzmed.ac.ir

Abstract

Purpose: Rivastigmine hydrogen tartrate (RHT) is commonly used for the treatment of mild to moderate Alzheimer’s disease (AD). The aim of this work was to formulate in-situ pluronic F-127 (PF-127) hydrogels containing Eudragit RL-100 (EU-RL) nanoparticles (NPs) in order to improve the therapeutic efficacy of RHT through the nasal route.

Methods: The NPs were prepared using different polymer to drug ratios and evaluated for their physicochemical characteristics, cellular uptake and in vitro cytotoxicity against lung adenocarcinoma cells (A459). PF-127 nanoformulations were prepared via cold method and analyzed in terms of physicochemical properties and drug release profiles. The nanoformulations and plain drug gel were then assessed by ex vivo permeation studies across the sheep nasal mucosa.

Results: The EU-RL NPs exhibited a particle size within the range of 118 to 154 nm and positive zeta potential values of 22.5 to 30 mV with an approximately spherical shape. Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and X-ray powder diffraction (XRPD) suggested no drug to polymer interaction through the preparation of nanoformulations. The RHT-loaded NPs exhibited an acceptable cytocompatibility with a time- and dose-dependent cellular internalization.

Conclusion: Our results clearly indicated the potential of nanoformulations as controlled release systems to improve the therapeutic efficacy of RHT through the intranasal administration

Keywords: Cytotoxicity, Eudragit, Hydrogel, Nanoparticle, Nasal, Rivastigmine
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 721

Your browser does not support the canvas element.


PDF Download: 581

Your browser does not support the canvas element.

Submitted: 28 Feb 2019
Revision: 02 Jul 2019
Accepted: 09 Oct 2019
ePublished: 11 Dec 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)